PFA-100 closure times in preoperative screening in 500 pediatric patients

 

 Buy Article Permissions and Reprints

Summary

Three to five percent of patients undergoing surgery have either an acquired or congenital platelet defect or von Willebrand disease (vWD). The predictive value of preoperative coagulation screening is questionable. PFA-100 is now routinely used in preoperative screening in our pediatric outpatient service. We wanted to assess whether the PFA-100 would help to identify patients with primary haemostatic defects or if the additional use of PFA-100 would add to the problem of unnecessary pathologic preoperative laboratory values resulting in delay of surgical procedure. We investigated 500 children consecutively seen in our outpatient service before surgery. Blood cell count, aPTT, PFA-100 closure times (CT) were done in all patients. If abnormalities were found, the patient was presented to a haemostatic expert. vWF:AG, R:Cof and factorVIII were analysed in all patients with prolonged closure times and APTT values. One hundred twenty-six patients (25.2%) showed abnormalities in APTT and/or PFA-100. Further investigations in 89 of these 126 patients did not yield a specific diagnosis; neither diagnostic criteria for impaired haemostasis were found by questionnaire. None of these 89 patients had a bleeding complication during surgery. Forty-eight patients showed prolonged CTs. Twelve patients with low vWF:AG were detected, 10 of these patients were found by PFA-100. Four of these patients did present with normal APTT values. Our study shows that similar to the APTT the PFA-100 is probably only a good screening method when a haemostatic defect in a patient is clinically likely, especially to screen forVWD, and the test should not be used in general unselective screening.

• References

• 1 Koscielny J, Ziemer S, Radtke H. et al. A practical concept for preoperative identification of patients with impaired primary hemostasis. Clin Appl Thromb Hemost 2004; 10: 195-204.
  CrossrefPubMedGoogle Scholar
• 2 Chee YL, Greaves M. Role of coagulation testing in predicting bleeding risk. Hematol J 2003; 4: 373-378.
  CrossrefPubMedGoogle Scholar
• 3 Houry S, Georgeac C, Hay JM. et al. A prospective multi-cente revaluation of preoperative hemostatic screening tests. Am J Surg 1995; 170: 19-23.
  CrossrefPubMedGoogle Scholar
• 4 Kitchens CS. To bleed or not to bleed? Is that the question for the PTT?. J Thromb Haemost 2005; 3: 2607-2611.
  CrossrefPubMedGoogle Scholar
• 5 Cochrane AL, Chapmann PJ, Oldham PD. Observ-ers errors in taking medical histories. Lancet 1951; 260: 1007-1009.
  PubMedGoogle Scholar
• 6 Montgomery RR, Kroner PA. von Willebrand disease: a common pediatric disorder. Pediatr Ann 2001; 30: 534-540.
  CrossrefPubMedGoogle Scholar
• 7 Sutor AH. The bleeding time in pediatrics. Semin Thromb Hemost 1998; 24: 531-543.
  Article in Thieme ConnectPubMedGoogle Scholar
• 8 Kundu SK, Heilmann EJ, Sio R. et al. Characterisation of an in vitro platelet analyser, PFA-100. Clin Appl Thromb Hemost 1996; 2: 241-249.
  CrossrefPubMedGoogle Scholar
• 9 Fressinaud E, Veyradier A, Truchaud F. et al. Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases. Blood 1998; 91: 1325-1331.
  PubMedGoogle Scholar
• 10 Cattaneo M, Federici AB, Lecchi A. et al. Evaluation of the PFA-100 system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease. Thromb Haemost 1999; 82: 35-39.
  Article in Thieme ConnectPubMedGoogle Scholar
• 11 Dean JA, Blanchette VS, Carcao MD. et al. von Willebrand disease in a pediatric-based population--comparison of type 1diagnostic criteriaand use of the PFA-100 and a von Willebrand factor/collagen-binding assay. Thromb Haemost 2000; 84: 401-409.
  Article in Thieme ConnectPubMedGoogle Scholar
• 12 Gallistl S, Muntean W, Leschnik B. et al. Longer aPTT values in healthy children than in adults: no single cause. Thromb Res 1997; 88: 355-359.
  CrossrefPubMedGoogle Scholar
• 13 Muntean W, Finding K, Leschnik B. Partial thromboplastin times are longer in healthy children than in adults. Thromb Haemorrh Disorders 1992; 6: 23-25.
  PubMedGoogle Scholar
• 14 Carcao M, Blanchette VS, Dean JA. et al. The platelet function analyzer (PFA-100) a novel in-vitrosystemfor evaluation of primary haemostasis. Br J Haematol 1998; 101: 70-73.
  CrossrefPubMedGoogle Scholar
• 15 Mammen EF, Comp PC, Gosselin R. et al. PFA-100 system: a new method for assessment of platelet function. Semin Thromb Hemost 1998; 24: 195-202.
  Article in Thieme ConnectPubMedGoogle Scholar
• 16 Roschitz B, Sudi K, Kostenberger M. et al. Shorter PFA-100 closure times in neonates than in adults: role of red cells, white cells, platelets and von Willebrand factor. Acta Paediatr 2001; 90: 664-670.
  CrossrefPubMedGoogle Scholar
• 17 Vincentelli A, Susen S, Le Tourneau T. et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med 2003; 349: 343-349.
  CrossrefPubMedGoogle Scholar
• 18 Hayward CPM, Harrison P, Cattaneo M. et al. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006; 4: 312-319.
  CrossrefPubMedGoogle Scholar
• 19 Koscielny J, Kiesewetter H, Tempelhoff GF. More on: platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006; 4: 1426-1427.
  CrossrefPubMedGoogle Scholar
• 20 Serebruany VL. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function: a rebuttal. J Thromb Haemost 2006; 4: 1428-1429.
  CrossrefPubMedGoogle Scholar
• 21 Kratzer MAA, Kretschmer V. Platelet function analyzer (PFA)-100 closure time in the evaluation of plateletdisorders and platelet function- a rebuttal. J Thromb Haemost 2006; 4: 1429-1431.
  CrossrefPubMedGoogle Scholar
• 22 Hayward CPM, Harrison P, Cattaneo M. et al. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function: reply to a rebuttal. J Thromb Haemost 2006; 4: 1433-1434.
  CrossrefPubMedGoogle Scholar
• 23 Manning SC, Beste D, McBride T. et al. An assessment of preoperative coagulation screening for tonsil-lectomy and adenoidectomy. Int J Pediatr Otorhinolaryngol 1987; 13: 237-244.
  CrossrefPubMedGoogle Scholar
• 24 Werner EJ, Broxson EH, Tucker EL. et al. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr 1993; 123: 893-898.
  CrossrefPubMedGoogle Scholar
• 25 Rodeghiero F, Castamann G, Dini E. Epidemiological investigation of the prevalence of von Willebrand´s disease. Blood 1987; 69: 545-549.
  PubMedGoogle Scholar
• 26 Harrison P. The role of PFA-100 testing in the investigation and management of haemostatic defects in children and adults. Br J Haematol 2005; 130: 3-10.
  CrossrefPubMedGoogle Scholar
• 27 Mizumoto H, Maihara T, Hiejima E. et al. Transient antiphospholipid antibodies associated with acute infections in children: a report of three cases and a review of the literature. Eur J Pediatr 2006; 165: 484-488.
  CrossrefPubMedGoogle Scholar
• 28 Edlinger G, Gallistl S, Muntean W. Lupus anticoagulant and factor XII acitivity in children with prolonged PTT. Thromb Res 1996; 5: 403-404.
  PubMedGoogle Scholar